No Data
US Stock MarketDetailed Quotes
NMRA Neumora Therapeutics
Watchlist
12.080
+0.170+1.43% Close 11/28 16:00 ET
12.0800.0000.00%
Post 16:01 ET
12.135High11.800Low131.05KVolume
11.830Open11.910Pre Close1.58MTurnover0.89%Turnover RatioLossP/E (TTM)1.84BMarket Cap17.73952wk HighLossP/E (Static)152.70MShares9.35052wk Low3.60P/B177.70MFloat Cap17.739Historical High--Dividend TTM14.71MShs Float9.350Historical Low--Div YieldTTM2.81%Amplitude12.030Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Neumora Therapeutics Company
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
News
Neumora Therapeutics Has Initiated A Phase 1 Single Ascending Dose / Multiple Ascending Dose Study Of NMRA-266 In Healthy Adult Participants For Schizophrenia And Other Neuropsychiatric Disorders
Neumora Therapeutics Has Initiated A Phase 1 Single Ascending Dose / Multiple Ascending Dose Study Of NMRA-266 In Healthy Adult Participants For Schizophrenia And Other Neuropsychiatric Disorders
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
WATERTOWN, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the initiation of a Phase 1
Neumora Therapeutics(NMRA.US) 10% Shareholder Buys US$412.14K in Common Stocks
$Neumora Therapeutics(NMRA.US)$ 10% Shareholder ARCH Venture Partners XII, LLC purchased 35,010 shares of Common Stocks on Nov 13, 14, 2023 at an average price of $11.77 for a total value of $412.14K.
Comments
CEO of Neumora, Henry Gosebruch, values Dr. Lenz's successful trial experience and neuroscience expertise for their pipeline development. Dr. Lenz is excited to contribute significantly to Neumora's R&D and neuropsychiatry programs.
Press Release: Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
Top squeeze stocks
$Axcella Health(AXLA.US$ Ranked #1 by Fintel. Its next run should take it to about 14.90.
$Ontrak(OTRK.US$ Has been out of shares for a week. Small float and cheap price. Can run as high as 2.94 when it finally does get volume.
$Neumora Therapeutics(NMRA.US$ Recent IPO and has been steady moving up from its low of 9.80. Now comes the bigger gap ups . 17.74 is its breakout.
$Prestige Wealth(PWM.US$ Seems to have found bottom at 3.10. If it has ER on October 6 that is. S...
$Ontrak(OTRK.US$ Has been out of shares for a week. Small float and cheap price. Can run as high as 2.94 when it finally does get volume.
$Neumora Therapeutics(NMRA.US$ Recent IPO and has been steady moving up from its low of 9.80. Now comes the bigger gap ups . 17.74 is its breakout.
$Prestige Wealth(PWM.US$ Seems to have found bottom at 3.10. If it has ER on October 6 that is. S...
7
9
McHTp
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--